| Outcome Measures: |
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability, Each subject will be followed for the duration of 6 hospital stays, an expected average of 5 weeks | Secondary: Pharmacokinetic parameters, PK parameters are including: Cmax, Cmin, Cavg, Cmin,i , Tmax, Tlast, t1/2, AUCτ, AUC0-t, AUC0-inf, % Fluctuation, Apparent body clearance following extravascular dosing (CL/F), Vz/F, Aet1-t2, Ae0-t, fe0-t, Renal clearance (CLR), Accumulation index (AI) and Accumulation ration (AR), 33 time points during 12 days (including measurements before dosing)|Pharmacodynamic parameters, PD parameters are including: Emax, Emin, Time to maximum effect (TEmax), TEmin, Area under the response versus time curve during a dosing interval ( AUECτ) and Area under the response versus time curve from time zero to the time of last quantifiable response (AUEC0-t), 34 time points during 10 days (including measurements before dosing)
|
